An approach to local immunotoxicity induced by adjuvanted vaccines

International Immunopharmacology

Volumn 17, Issue 3, 2013, Pages 526-536

  Batista Duharte, Alexander ^a   Portuondo, Deivys ^b   Carlos, Iracilda Zeppone ^b   Pérez, Oliver ^c  

^a Immunotoxicology Laboratory   (Cuba)

^b SÃO PAULO STATE UNIVERSITY UNESP   (Brazil)

^c FINLAY INSTITUTE   (Cuba)

Author keywords

Action mechanism; Adjuvant; Immunotoxicity; Local reaction; Vaccine

Indexed keywords

BCG VACCINE; POLIOMYELITIS VACCINE; VACCINE;

ADAPTIVE IMMUNITY; ANTIGEN PRESENTING CELL; ARTHUS PHENOMENON; ARTICLE; BCG VACCINATION; CARCINOGENESIS; DELAYED HYPERSENSITIVITY; DRUG INDUCED DISEASE; GRANULOMA; HUMAN; IMMUNIZATION; IMMUNOTOXICITY; INJECTION SITE NODULE; INNATE IMMUNITY; LYMPHADENITIS; LYMPHATIC DRAINAGE; LYMPHOID HYPERPLASIA; PERSIAN GULF SYNDROME; PRIORITY JOURNAL; PSEUDOLYMPHOMA; SUBCUTANEOUS NODULE; TUBERCULOSIS; URTICARIA;

ACTION MECHANISM; ADJUVANT; IMMUNOTOXICITY; LOCAL REACTION; VACCINE;

ADJUVANTS, IMMUNOLOGIC; ANIMALS; HUMANS; SKIN; VACCINES;

EID: 84884519475     PISSN: 15675769     EISSN: 18781705     Source Type: Journal    
DOI: 10.1016/j.intimp.2013.07.025     Document Type: Review

References (131)

1. B. Pulendran, and R. Ahmed Immunological mechanisms of vaccination Nat Immunol 12 6 2011 509 517
2. A. Batista-Duharte, E. Lindblad, and E. Oviedo Progress in understanding adjuvant immunotoxicity mechanisms Toxicol Lett 203 2011 97 105
3. R.K. Gupta, E.H. Relyveld, E.B. Lindblad, B. Bizzini, S. Ben-Efraim, and C.K. Gupta Adjuvants - a balance between toxicity and adjuvanticity Vaccine 11 1993 293 306 (Pubitemid 23061171)
4. K. Goldenthal, J.A. Cavagnaro, C. Alving, and F.R. Vogel Safety evaluation of vaccine adjuvants: National Cooperative Vaccine Development Meeting Working Group AIDS Res Hum Retroviruses 9 Suppl. 1 1993 S47 S51
5. V.E. Schijns Unraveling "the immunologists' dirty little secret" V.E. Schijns, D.T. O'Hagan, Immunopotentiators in modern vaccines 1st ed. 2006 Elsevier Acad Press USA 1 16
6. R.L. Coffman, A. Sher, and R.A. Seder Vaccine adjuvants: putting innate immunity to work Immunity 33 2010 492 503
7. T.M. Hauguel, and Ch.J. Hackett Rationally-designed vaccine adjuvants: separating efficacy from toxicity Front Biosci 13 2008 2806 2813 (Pubitemid 351589200)
8. R.M. Zinkernagel, S. Ehl, P. Aichele, S. Oehen, T. Kundig, and H. Hengarten Antigen localization regulates immune responses in a dose- and time-dependent fashion: a geographical view of immune reactivity Immunol Rev 156 1997 199 209 (Pubitemid 27197203)
9. V.J.C. Schijns Mechanisms of vaccine adjuvant activity: initiation and regulation of immune responses by vaccine adjuvants Vaccine 21 2003 829 831
10. H.L. Wilson, J. Kovacs-Nolan, L. Latimer, R. Buchanan, S. Gomis, and L. Babiuk A novel triple adjuvant formulation promotes strong, Th1-biased immune responses and significant antigen retention at the site of injection Vaccine 28 2010 8288 8299
11. -/-) mutant mice Exp Med 185 1997 2157 2170 (Pubitemid 27265999)
12. C.F. Barker, and R.E. Billingham The role of regional lymphatics in the skin homograft response Transplantation 5 1967 962 966
13. M.A. Swartz, J.A. Hubbell, and S.T. Reddy Lymphatic drainage function and its immunological implications: from dendritic cell homing to vaccine design Sem Immunol 20 2008 147 156
14. G.J. Randolph, V. Angeli, and M.A. Swartz Dendritic cell trafficking to lymph nodes via lymphatic vessels Nat Rev Immunol 5 2005 1 12
15. L.A. Johnson, S. Clasper, A.P. Holt, P.F. Lalor, D. Baban, and D.G. Jackson An inflammation-induced mechanism for leukocyte transmigration across lymphatic vessel endothelium J Exp Med 203 12 2006 2763 2777 (Pubitemid 44833351)
16. M. de Veer, J. Kemp, J. Chatelier, M.J. Elhay, and E.N.T. Meeusen The kinetics of soluble and particulate antigen trafficking in the afferent lymph, and its modulation by aluminum-based adjuvant Vaccine 28 2010 6597 6602
17. D.T. O'Hagan, and N.M. Valiante Recent advances in the discovery and delivery of vaccine adjuvants Nat Rev Drug Discov 2 2003 727 735 (Pubitemid 37361788)
18. Ch.A. Janeway Jr The immune system evolved to discriminate infectious non-self from non-infectious self Immunol Today 13 1992 11 16
19. D.M. Underhill, and A. Ozinsky Toll-like receptors: key mediators of microbe detection Curr Opin Immunol 14 1 2002 103 110 (Pubitemid 34085113)
20. T. Kawai, and Sh. Akira The role of pattern-recognition receptors in innate immunity: update on Toll-like receptors Nat Immunol 11 5 2010 373 384
21. F. Martinon, A. Mayor, and J. Tschopp The inflammasomes: guardians of the body Ann Rev Immunol 27 2009 229 265
22. E. De Gregorio, U. D'Oro, and A. Wack Immunology of TLR-independent vaccine adjuvants Curr Opin Immunol 21 2009 339 345
23. P. Matzinger Tolerance, danger, and the extended family Ann Rev Immunol 12 1994 991
24. P. Scaffidi, T. Misteli, and M.E. Bianchi Release of chromatin protein HMGB1 by necrotic cells triggers inflammation Nature 418 2002 191 195 (Pubitemid 34773774)
25. M.E. Bianchi HMGB1 loves company J Leukoc Biol 86 2009 573 576
26. G. Ng, E. Chau, and Y. Shi Recent developments in immune activation by uric acid crystals Arch Immunol Ther Exp 58 2010 273 277
27. L. Zitvogel, O. Kepp, and G. Kroemer Decoding cell death signals in inflammation and immunity Cell 140 2010 798 804
28. G.A. Culora, A.D. Ramsay, and J.M. Theaker Aluminium and injection site reactions J Clin Pathol 49 1996 844 847 (Pubitemid 26338567)
29. E. Rothstein, K.S. Kohl, L. Ball, S.A. Halperin, N. Halsey, and S.J. Hammer Nodule at injection site as an adverse event following immunization: case definition and guidelines for data collection, analysis, and presentation Vaccine 22 2004 575 585 (Pubitemid 38114884)
30. E.B. Lindblad Safety evaluation off vaccine adjuvants M. Singh, Vaccine adjuvants and delivery systems 2007 John Wiley and Sons Inc.
31. O. Soehnlein, L. Lindbom, and C. Weber Mechanisms underlying neutrophil-mediated monocyte recruitment Blood 114 2009 4613 4623
32. O. Soehnlein, and L. Lindbom Phagocyte partnership during the onset and resolution of inflammation Immunology 10 2010 427 439
33. D.A. Willoughby, A.R. Moore, P.R. Colville-Nash, and D. Gilroy Resolution of inflammation Int J Immunopharmacol 22 2000 1131 1135 (Pubitemid 32012972)
34. C.U. Brand, T. Hunziker, and L.R. Braathen Isolation of human skin-derived lymph: flow and output of cells following sodium lauryl sulphate-induced contact dermatitis Arch Dermatol Res 284 3 1992 123 126
35. M. Fischer, U.K. Franzeck, I. Herrig, U. Costanzo, S. Wen, and M. Schiesser Flow velocity of single lymphatic capillaries in human skin Am J Phys 39 1 1996 358 363
36. W.J. Herbert Antigenicity of soluble protein in the presence of high levels of antibody: a possible mode of action of the antigen adjuvants Nature 210 1966 747 748
37. D.E.S. Stewart-Tull Freund-type mineral oil adjuvant emulsion D.E.S. Stewart-Tull, The theory and practical application of adjuvants 1995 John Wiley & Sons Ltd. 1 19
38. N. Goto, H. Kato, J. Maeyama, M. Shibano, T. Saito, and J. Yamaguchi Local tissue irritation effects and adjuvant activities of calcium phosphate and aluminum hydroxide with different physical properties Vaccine 15 1997 1364 1371 (Pubitemid 27397815)
39. T. Storni, T.M. Kundig, G. Senti, and P. Johansen Immunity in response to particulate antigen-delivery systems Adv Drug Deliv Rev 57 2005 333 355 (Pubitemid 39555501)
40. S. Noe, M. Green, H. HogenEsch, and S. Hem Mechanism of immunopotentiation by aluminum-containing adjuvants elucidated by the relationship between antigen retention at the inoculation site and the immune response Vaccine 28 2010 3588 3594
41. E.B. Lindblad Mineral adjuvants V.E. Schijns, D.T. O'Hagan, Immunopotentiators in modern vaccines 1st ed. 2006 Elsevier Acad Press USA 217 233
42. J.H. Eldridge, J.K. Staas, J.A. Meulbroek, T.R. Tice, and R.M. Gilley Biodegradable and biocompatible poly(d, l-lactide-co-glycolide) microspheres as an adjuvant for staphylococcal enterotoxin B toxoid which enhances the level of toxin-neutralizing antibodies Infect Immun 59 1991 2978 2986
43. D.T. O'Hagan, H. Jeffery, and S.S. Davis Long-term antibody responses in mice following subcutaneous immunization with ovalbumin entrapped in biodegradable microparticles Vaccine 11 1993 965 969 (Pubitemid 23218807)
44. D.R. Ciocca, P. Frayssinet, and D.F. Cuello-Carrión A pilot study with a therapeutic vaccine based on hydroxyapatite ceramic particles and self-antigens in cancer patients Cell Stress Chaperones 12 1 2007 33 43 (Pubitemid 47403326)
45. D.O. Co, L.H. Hogan, S. Il-Kim, and M. Sandor T cell contribution to the different phases of granuloma formation Immunol Lett 92 2004 135 142 (Pubitemid 38470060)
46. P.M.H. Heegaard, L. Dedieu, N. Johnson, M.F. Le Potier, M. Mockey, and F. Mutinelli Adjuvants and delivery systems in veterinary vaccinology: current state and future developments Arch Virol 156 2011 183 202
47. J.W. Steiner, B. Langer, and D.L. Schatz The local and systemic effects of Freund's adjuvant and its fractions Arch Pathol 70 1960 424 434
48. S.Y. Leclercq, R.M. Marques, L.M. Branco, P.C. Cota, T.F. Campos, and J.A. Gomes Evaluation of water-in-oil-in-water multiple emulsion and microemulsion as potential adjuvants for immunization with rabies antigen Eur J Pharm Sci 43 2011 378 385
49. M.A. Dommergues, F. de La Rocque, C. Guy, A. Lécuyer, A. Jacquet, and N. Guérin Local and regional adverse reactions to BCG-SSI® vaccination: a 12-month cohort follow-up study Vaccine 27 2009 6967 6973
50. R.K. Gherardi, M. Coquet, P. Cherin, L. Belec, P. Moretto, and P.A. Dreyfus Macrophagic myofasciitis lesions assess long-term persistence of vaccine -derived aluminium hydroxide in muscle Brain 124 2001 1821 1831 (Pubitemid 32845443)
51. R.K. Gherardi, and F.J. Authier Macrophagic myofasciitis: characterization and pathophysiology Lupus 21 2012 184 189
52. F. Verdier, R. Burnett, Moretto P. Michelet-Habchi, F. Fievet-Groyne, and E. Sauzeat Aluminium assay and evaluation of the local reaction at several time points after intramuscular administration of aluminiun containing vaccines in the cynomolgus monkey Vaccine 23 11 2005 1359 1367 (Pubitemid 40127328)
53. Y. Shoenfeld, and N. Agmon-Levin "ASIA" - autoimmune/ inflammatory syndrome induced by adjuvants J Autoimmun 36 2011 4 8
54. X.D. Yang, V. Coriolan, K. Murthy, D.T. Schultz, and D. Golenbock Proinflammatory phenotype of vascular smooth muscle cells: role of efficient Toll-like receptor 4 signaling Am J Physiol Heart Circ Physiol 289 2005 H1069 H1076
55. S.K. Lim Freund adjuvant induces TLR2 but not TLR4 expression in the liver of mice Int Immunopharmacol 3 1 2003 115 118
56. Y. Yang, Wu. Ch, and W. Morrow Cell death induced by vaccine adjuvants containing surfactants Vaccine 22 2004 1524 1536 (Pubitemid 38446931)
57. Y. Yang, and S. Shen Enhanced antigen delivery via cell death induced by the vaccine adjuvants Vaccine 25 2007 7763 7772 (Pubitemid 47588529)
58. C. Kensil, U. Patel, M. Lennick, and D. Marciani Separation and characterization of saponins with adjuvant activity from Quillaja saponaria Molina cortex Int Immunol 146 1991 431 437
59. J. Vitoriano-Souza, A.B. Reis, N.D. Moreira, R.C. Giunchetti, R. Correa-Oliveira, and C.M. Carneiro Kinetics of cell migration to the dermis and hypodermis in dogs vaccinated with antigenic compounds of Leishmania braziliensis plus saponin Vaccine 26 2008 3922 3931
60. P. Marrack, A. McKee, and M. Munks Towards an understanding of the adjuvant action of aluminium Nat Rev Immunol 9 4 2009 287 293
61. T. Marichal, K. Ohata, D. Bedoret, C. Mesnil, C. Sabatel, and K. Kobiyama DNA released from dying host cells mediates aluminum adjuvant activity Nat Med 17 8 2011 996 1002
62. A. Helenius, and K. Simons Solubilization of membranes by detergents Biochim Biophys Acta 415 1975 29
63. S.M. Bhairi Detergents: a guide to the properties and uses of detergents in biological systems 2001 Calbiochem-Novabiochem Co.
64. Y. Zheng, M. Humphry, J.J. Maguire, M.R. Bennett, and M.C.H. Clarke Intracellular interleukin-1 receptor 2 binding prevents cleavage and activity of interleukin-1α. Controlling necrosis-induced sterile inflammation immunity Immunity 38 2 2013 285 295
65. S. Gallucci, M.L. Olkema, and P. Matzinger Natural adjuvants: endogenous activators of dendritic cells Nat Med 5 11 1999 1249 1255 (Pubitemid 29535601)
66. E.S. Magalhaes, C.N. Paiva, H.S. Souza, A.S. Pyrrho, D. Mourao-Sa, and R.T. Figueiredo Macrophage migration inhibitory factor is critical to interleukin-5-driven eosinophilopoiesis and tissue eosinophilia triggered by Schistosoma mansoni infection FASEB J 23 2009 1262 1271
67. C.N. Paiva, R.H. Arras, E.S. Magalhaes, L.S. Alves, L.P. Lessa, and M.H. Silva Migration inhibitory factor (MIF) released by macrophages upon recognition of immune complexes is critical to inflammation in Arthus reaction J Leuk Biol 85 2009 855 861
68. A.M. Mowat, A.M. Donachie, G. Reid, and O. Jarrett Immune-stimulating complexes containing Quil A and protein antigen prime class I MHC-restricted T lymphocytes in vivo and are immunogenic by the oral route Immunology 72 1991 317 322
69. K.J. Maloy, A.M. Donachie, D.T. O'Hagan, and A.M. Mowat Induction of mucosal and systemic immune responses by immunization with ovalbumin entrapped in poly(lactide-co-glycolide) microparticles Immunology 81 1994 661 667 (Pubitemid 24246520)
70. E. Furrie, R.E. Smith, M.W. Turner, S. Strobel, and A.M. Mowat Induction of local innate immune responses and modulation of antigen uptake as mechanisms underlying the mucosal adjuvant properties of immune stimulating complexes (ISCOMS) Vaccine 20 2002 2254 2262 (Pubitemid 34497036)
71. G.R. Matyas, N.M. Wassef, M. Rao, and C.R. Alving Induction and detection of antibodies to squalene J Immunol Methods 245 1-2 2000 1 14
72. P.B. Asa, R.B. Wilson, and R.F. Garry Antibodies to squalene in recipients of anthrax vaccine Exp Mol Pathol 73 1 2002 19 27 (Pubitemid 34775454)
73. C. Ponvert Allergic and non-allergic hypersensitivity reactions to toxoid-containing vaccines Arch Pediatrie 16 4 2009 391 395
74. M. Karaayvaz, and N. Ozanguc Recall urticaria: a case report J Allergy Clin Immunol 97 1996 1419 1420 (Pubitemid 26192297)
75. K. Rinn, K. Schiffman, H.O. Otero, and M.L. Disis Antigen-specific recall urticaria to a peptide-based vaccine Allergy Clin Immunol 104 1999 240 242 (Pubitemid 29364512)
76. J.K. Simon, and R. Edelman Clinical evaluation of adjuvants V.E. Schijns, D.T. O'Hagan, Immunopotentiators in modern vaccines 1st ed. 2006 Elsevier Acad Press USA 1 16
77. D.M. Gordon, R.E. Duffy, D.G. Heppner, J.A. Lyon, J.S. Williams, and D. Scheumann Phase I safety and immunogenicity testing of clinical lots of the synthetic Plasmodium falciparum vaccine SPf66 produced under good manufacturing procedure conditions in the United States Am J Trop Med Hyg 55 1996 63 68
78. R. Edelman, S.S. Wasserman, J.G. Kublin, S.A. Bodison, E.H. Nardin, and G.A. Oliveira Immediate-type hypersensitivity and other clinical reactions in volunteers immunized with a synthetic multi-antigen peptide vaccine (PfCS-MAPlNYU) against Plasmodium falciparum sporozoites Vaccine 21 2002 269 280 (Pubitemid 35350854)
79. Y.H. Hsu, Y.H. Wang, and W.Y. Hsu Kawasaki disease characterized by erythema and induration at the Bacillus Calmette-Guerin and purified protein derivative inoculation sites Pediatr Infect Dis J 6 6 1987 576 577
80. M. Weinstein Inflammation at a previous inoculation site: an unusual presentation of Kawasaki disease CMAJ 174 4 2006 459 460
81. M.J. Hendrick, and J.J. Brooks Postvaccinal sarcomas in the cat: histology and immunohistochemistry Vet Pathol 31 1994 126 129 (Pubitemid 24052911)
82. F.E. Jelinek Postinflammatory sarcoma in cats Exp Toxicol Pathol 55 2003 167 172
83. J.S. Munday, N.L. Stedman, and L.J. Richey Histology and immunohistochemistry of seven ferret vaccination-site fibro-sarcomas Vet Pathol 40 2003 288 293 (Pubitemid 38393578)
84. M. Vascellari, E. Melchiotti, M.A. Bozza, and F. Mutinelli Fibrosarcomas at presumed sites of injection in dogs: characteristics and comparison with non-vaccination site fibrosarcomas and feline post-vaccinal fibrosarcomas J Vet Med A 50 2003 286 291 (Pubitemid 41726256)
85. B. Madwell, S.M. Griffey, M.C. McEntee, V.J. Leppert, and R.J. Munn Feline vaccine associated fibrosarcoma: an ultrasound study of 20 tumors (1996-1999) Vet Pathol 38 2 2001 196 202
86. P.R. Nambiar, M.L. Jackson, J.A. Ellis, B.J. Chelack, B.A. Kidney, and D.M. Haines Immunohistochemical detection of tumor suppressor gene p53 protein in feline injection site-associated sarcomas Vet Pathol 38 2 2001 236 238 (Pubitemid 33621702)
87. S.S. Couto, S.M. Griffey, P.C. Duarte, and B.R. Madawewll Feline vaccine-associated fibrosarcoma: morphologic distinctions Vet Pathol 39 2002 33 41
88. K. Zabielska, K.R. Lechowski, M. Król, K.M. Pawłowski, T. Motyl, and I. Dolka Derivation of feline vaccine-associated fibrosarcoma cell line and its growth on chick embryo chorioallantoic membrane - a new in vivo model for veterinary oncological studies Vet Res Commun 36 2012 227 233
89. P.H. Kass, W.L. Spangler, M.J. Hendrick, L.D. McGill, D.G. Esplin, and S. Lester Multicenter case-control study of risk factors associated with development of vaccine-associated sarcomas in cats J Am Vet Med Assoc 223 2003 1283 1299
90. F. Colotta, P. Allavena, A. Sica, C. Garlanda, and A. Mantovani Cancer-related inflammation, the seventh hallmark of cancer: links to genetic instability Carcinogenesis 30 2009 1073 1081
91. E. Maubec, L. Pinquier, M. Viguier, F. Caux, E. Amsler, and S. Aractingin Vaccination-induced cutaneous pseudolymphoma J Am Acad Dermatol 52 4 2005 623 629 (Pubitemid 40585432)
92. P.A. Easton, and E.S. Hershfield Lymphadenitis as a late complication of BCG vaccination Tubercle 65 3 1984 205 208 (Pubitemid 14027719)
93. A. Lotte, O. Wasz-Hockert, N. Poisson, N. Dumitrescu, M. Verron, and E. Couvet BCG complications. Estimates of the risks among vaccinated subjects and statistical analysis of their main characteristics Adv Tuberc Res 21 1984 107 193
94. S.S.S. Teo, N. Smeulders, and D.V. Shingadia BCG vaccine-associated suppurative lymphadenitis Vaccine 23 2005 2676 2679 (Pubitemid 40380812)
95. E. Bukhari, M. Alzahrani, S. Alsubaie, A. Alrabiaah, and F. Alzamil Bacillus Calmette-Guerin lymphadenitis: a 6-year experience in two Saudi hospitals Indian J Pathol Microbiol 55 2 2012 202 205
96. W. Chen, G.B. Patel, H. Yan, and J. Zhang Recent advances in the development of novel mucosal adjuvants and antigen delivery systems Hum Vaccin 6 9 2010 706 714
97. L.B. Lawson, E.B. Norton, and J.D. Clements Defending the mucosa: adjuvant and carrier formulations for mucosal immunity Curr Opin Immunol 23 2011 414 420
98. K.B. Walker, M.H. Serwonska, F.H. Valone, W.S. Harkonen, O.L. Frick, and K.H. Scriven Distinctive patterns of release of neuroendocrine peptides after nasal challenge of allergic subjects with ryegrass antigen J Clin Immunol 8 1988 108 113
99. M.I. Ugwoke, N. Verbeke, and N. Kinget The biopharmaceutical aspects of nasal mucoadhesive drug delivery J Pharm Pharmacol 53 2001 3 22
100. K. Fujihashi, T. Koga, F.W. van Ginkel, Y. Hagiwara, and J.R. McGhee A dilemma for mucosal vaccination: efficacy versus toxicity using enterotoxin-based adjuvants Vaccine 20 2002 2431 2438 (Pubitemid 34615580)
101. M. Mutsch, W. Zhou, P. Rhodes, M. Bopp, R.T. Chen, and T. Linder Use of the inactivated intranasal influenza vaccine and the risk of Bell's palsy in Switzerland N Engl J Med 350 2004 896 903 (Pubitemid 38252537)
102. D.J. Lewis, Z. Huo, S. Barnett, I. Kromann, R. Giemza, and E. Galiza Transient facial nerve paralysis (Bell's palsy) following intranasal delivery of a genetically detoxified mutant of Escherichia coli heat labile toxin PLoS One 4 2009 e6999
103. M. Lindqvist, N. Navabi, M. Jansson, E. Samuelson, A. Sjöling, and Ch. Örndal Local cytokine and inflammatory responses to candidate vaginal adjuvants in mice Vaccine 28 2010 270 278
104. P. Matzinger The evolution of the danger theory Expert Rev Clin Immunol 8 4 2012 311 317
105. L.B. Holt Developments in diphtheria prophylaxis 1950 Heinemann London 67 99
106. S. Iyer, H. HogenEsch, and S.L. Hem Relationship between the degree of antigen adsorption to aluminum hydroxide adjuvant in interstitial fluid and antibody production Vaccine 21 2003 1219 1223 (Pubitemid 36139952)
107. S. Calabro, M. Tortoli, B. Baudner, A. Pacitto, M. Cortese, and D. O'Hagan Vaccine adjuvants alum and MF59 induce rapid recruitment of neutrophils and monocytes that participate in antigen transport to draining lymph nodes Vaccine 29 2011 1812 1823
108. I.H. Frazer, R.W. Tindle, G.J.P. Fernando, K. Malcolm, K. Herd, and S. McFadyn Safety and immunogenicity of HPV16E7/algammulin R.W. Tindle, Vaccines for human papillomavirus infection and anogenital disease 1999 R.G. Landes Company
109. Seppic Montanide™ IMS. An innovative range of adjuvants for vaccines and injectables P/0891/GB/03/November 2002 www.seppic.com
110. N. Petrovsky Novel human polysaccharide adjuvants with dual Th1 and Th2 potentiating activity Vaccine 24 Suppl. 2 2006 [S2-26-29]
111. J.F. Infante, S. Sifontes, V. Pérez, G. Bracho, T. Hernández, and C. Zayas Study of immunogenicity and local toxicity of the Neisseria meningitidis cochleate in Sprague Dawley rats VacciMonitor 18 1 2009 1 7
112. A. Batista-Duharte, V. Quattrocchi, V. Olivera, C. Langellotti, J.S. Pappalardo, and S. Di Giacomo Adjuvant effect of Cliptox on the protective immune response induced by an inactivated vaccine against foot and mouth disease virus in mice Vaccine 28 2010 6361 6366
113. N. Garçon, L. Segal, F. Tavares, and M. van Mechelen The safety evaluation of adjuvants during vaccine development. The AS04 experience Vaccine 29 2011 4453 4459
114. V. Gerdts Does adjuvanticity depend on the ability to recruit specific immune cells? Exp Rev vaccine 10 4 2011 433 435
115. V. Mata-Haro, C. Cekic, M. Martin, P.M. Chilton, C.R. Casella, and T.C. Mitchell The vaccine adjuvant monophosphoryl lipid A as a TRIF-biased agonist of TLR4 Science 316 2007 1628 1632 (Pubitemid 46982038)
116. R.T. Kenney, R.N. Regina, S. Pichyangkul, V.L. Price, and H.D. Engers Second meeting on novel adjuvants currently in/close to human clinical testing. World Health Organization-Organization Mondiale de la Sante Fondation Merieux, Annecy, France, 5-7 June 2000 Vaccine 20 2002 2155 2163 (Pubitemid 34497022)
117. L. Diggle, and J. Deeks Effect of needle length on incidence of local reactions to routine immunisation in infants aged 4 months: randomised controlled trial BMJ 321 2000 931 933
118. N. Petrovsky Freeing vaccine adjuvants from dangerous immunological dogma Expert Rev Vaccines 7 1 2008 7 10 (Pubitemid 351359053)
119. A. Batista-Duharte, M. Lastre, and O. Pérez Immunological adjuvants. Determinant factors in the efficacy-toxicity ratio of the contemporary vaccines Enferm Infecc Microbiol Clin 2013 10.1016/j.eimc.2012.11. 012 [pii: S0213-005X(12)00434-X, Epub ahead of print]
120. A.L. Engel, G.E. Holt, and H. Lu The pharmacokinetics of Toll-like receptor agonists and the impact on the immune system Exp Rev Clin Pharmacol 4 2 2011 275 289
121. F.R. Brennan, and G. Dougan Non-clinical safety evaluation of novel vaccines and adjuvants: new products, new strategies Vaccine 23 24 2005 3210 3222
122. A. Batista-Duharte, G.J. Murillo, U.M. Pérez, E.N. Tur, D.F. Portuondo, and O. Pérez Evaluation of the mucosal irritation of AFCo1 adjuvant by HET-CAM method VacciMonitor 20 1 2011 22 27
123. A. Vargas, M. Zeisser-Labouèbe, N. Lange, R. Gurny, and F. Delie The chick embryo and its chorioallantoic membrane (CAM) for the in vivo evaluation of drug delivery systems Adv Drug Deliv Rev 59 2007 1162 1176 (Pubitemid 47615205)
124. I. Beck, H. Gerlach, E. Burkhardt, and E.F. Kaleta Investigation of several selected adjuvants regarding their efficacy and side effects for the production of a vaccine for parakeets to prevent a disease caused by a paramyxovirus type 3 Vaccine 21 2003 1006 1022 (Pubitemid 36126437)
125. D.C. Waite, E.W. Jacobson, F.A. Ennis, R. Edelman, B. White, and R. Kammer Three double-blind, randomized trials evaluating the safety and tolerance of different formulations of the saponin adjuvant QS-21 Vaccine 19 2001 3957 3967 (Pubitemid 32566320)
126. A. Podda The adjuvanted influenza vaccines with novel adjuvants: experience with the MF59-adjuvanted vaccine Vaccine 19 2001 2673 2680 (Pubitemid 32234288)
127. R. Gluck, K.G. Burri, and I. Metcalfe Adjuvant and antigen delivery properties of virosomes Curr Drug Deliv 2 2005 395 400 (Pubitemid 41277771)
128. O. Pérez, A. Batista-Duharte, E. González, C. Zayas, J. Balboa, and M. Cuello Human prophylactic vaccine adjuvants and their determinant role in new vaccine formulations Braz J Med Biol Res 45 8 2012 681 692
129. L. Tiberio, L. Fletcher, J.H. Eldridge, and D.D. Duncan Host factors impacting the innate response in humans to the candidate adjuvants RC529 and monophosphoryl lipid A Vaccine 22 2004 1515 1523 (Pubitemid 38446930)
130. v) in healthy adults Hum Vaccin 6 7 2010 578 584
131. O. Perez, M. Lastre, O. Cabrera, J. del Campo, G. Bracho, and M. Cuello New vaccines require potent adjuvants like AFPL1 and AFCo1 Scand J Immunol 66 2007 271 277 (Pubitemid 47063207)